DexCom's Q3 results showed disappointing 2% revenue growth and a 26% decline in operating income. Click here to read my DXCM ...

DexCom, Inc. DXCM reported third-quarter 2024 adjusted earnings per share (EPS) of 45 cents, which beat the Zacks Consensus ...

DexCom, Inc. DXCM reported third-quarter ... The broader S&P 500 index has moved up 21.6% in the same period. Sensor and other revenues (96% of total revenues) increased 9% on a year-over-year ...

Sensor and other revenues (96% of total revenues ... Total assets amounted to $6.35 billion, down sequentially from $6.79 billion. DexCom reiterated its outlook for 2024 revenues.

DexCom's stock fell sharply after mixed Q2 earnings and lowering full-year guidance, signaling a revaluation phase with lower ...

DexCom, Inc. DXCM is scheduled to release third ... Currently, the Zacks Consensus Estimate for revenues is pegged at $991.6 million, indicating growth of 1.7% from the year-ago quarter’s ...

Potential robust contributions from the Sensor segment, and domestic and international revenue growth are likely to have been ...

Teri Lawver is leaving the diabetes tech company during a challenging time, with sales slowing after a workforce ...